Certain identified information has been omitted from this exhibit because it is not material and of the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. SAMSUNG BIOLOGICS CO., LTD. PRODUCT...Product Specific Agreement • December 23rd, 2021 • Environmental Impact Acquisition Corp • Biological products, (no disgnostic substances)
This Product Specific Agreement (this “PSA”) is made effective as of the date of last signature below (the “PSA Effective Date”) by and between GreenLight Biosciences, Inc., a Delaware corporation having its principal place of business at 200 Boston Avenue, Suite 1000, Medford, MA 02155 (“Client”) and Samsung Co., Ltd., a Korean corporation having its principal place of business at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
ContractProduct-Specific Agreement • February 24th, 2022
Product-Specific Agreement DOHODA KE SPECIFICKÉMU PŘÍPRAVKU This agreement (“Product-Specific Agreement”) is made and entered into as of<<insert date>> (“Product-Specific Agreement Effective Date”) by and between Tuto dohodu („dohodu ke specifickému přípravku“) uzavírají ke dni posledního podpisu smluvních stran a ke dni uveřejnění v registru smluv („datum účinnosti dohody kespecifickému přípravku“) mezi sebou EBMT, the European Group for Blood and Marrow transplantation, EBMT, Evropská společnostitransplantace krve a kostní pro legally represented by dřeně, kterou právně zastupuje hereinafter referred to as “EBMT”. dále jen „EBMT“. AND A Fakultní nemocnice Hradec Králové, adresa nemocniceSokolská 581, 500 05 Hradec Králové – Nový Hradec Králové represented by CEOprof. MUDr. Vladimír Palička, CSc., dr. h. c., ředitel, hereinafter referred to as “Poskytovatel” or “Participating Site”. Fakultní nemocnice Hradec Králové, Sokolská 581, 500 05 Hradec Králové – Nový H
SAMSUNG BIOLOGICS CO., LTD. PRODUCT SPECIFIC AGREEMENT – COMMERCIAL PRODUCT DRUG SUBSTANCEProduct Specific Agreement • July 25th, 2024 • Kiniksa Pharmaceuticals International, PLC • Pharmaceutical preparations
This Product Specific Agreement (this “PSA”) is made effective as of June 21, 2024 (the “PSA Effective Date”) by and between Kiniksa Pharmaceuticals (UK), Ltd., a private company organized under the laws of England and Wales with a Swiss branch office located at Grafenaustrasse 5, 6300 Zug, Switzerland (“Client”) and Samsung BioLogics Co., Ltd., a Korean corporation having its principal place of business at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Certain identified information has been excluded because it is both not material and would likely cause competitive harm if publicly disclosed. SAMSUNG BIOLOGICS CO., LTD. PRODUCT SPECIFIC AGREEMENT COMMERCIAL DRUG SUBSTANCEProduct Specific Agreement • August 14th, 2019 • CytoDyn Inc. • Pharmaceutical preparations
ContractProduct Specific Agreement • March 1st, 2021 • Fibrogen Inc • Pharmaceutical preparations
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.
SAMSUNG BIOLOGICS CO., LTD. PRODUCT SPECIFIC AGREEMENT - COMMERCIAL PRODUCT DRUG SUBSTANCEProduct Specific Agreement • November 7th, 2018 • Immunomedics Inc • In vitro & in vivo diagnostic substances
This Product Specific Agreement (this “PSA”) is made effective as of the date of last signature below (the “PSA Effective Date”) by and between Immunomedics, Inc., a Delaware corporation having its principal place of business at 300 The American Rd, Morris Plains, NJ 07950 (“Client”) and Samsung BioLogics Co., Ltd., a company with offices at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
ContractProduct-Specific Agreement • November 15th, 2021
Product-Specific Agreement DOHODA KE SPECIFICKÉMU PŘÍPRAVKU They conclude this agreement ("product-specific agreement") ("effective date of the product-specific agreement") with each other Tuto dohodu („dohodu ke specifickému přípravku“) uzavírají („datum účinnosti dohody ke specifickému přípravku“) mezi sebou EBMT, the European Group for Blood and Marrow transplantation, EBMT, Evropská společnosti protransplantace krve a kostní legally represented by A. Gusi dřeně, kterou právně zastupuje A. Gusi hereinafter referred to as “EBMT”. dále jen „EBMT“. AND A University Hospital Pilsen, Edvarda Beneše 1128/13, 305 99 Pilsen, represented by MUDr. Václav Šimánek, Ph.D., hereinafter referred to as "FN Plzeň" a XXX Department of Hematology and Oncology, Svobody Alley 80, Fakultní nemocnice Plzeň, Edvarda Beneše 1128/13, 305 99 Plzeň, kterou zastupuje MUDr. Václav Šimánek, Ph.D., dále jen „FN Plzeň“ aXXXHematologicko-onkologické oddělení, alej Svobody 80, 304 60 Plzeň „zúčast
ContractProduct-Specific Agreement • November 12th, 2021
Product-Specific Agreement DOHODA KE SPECIFICKÉMU PŘÍPRAVKU They conclude this agreement (“Product- Specific Agreement”) (“effective date the product-Specific Agreement”) with each other Tuto dohodu („dohodu ke specifickému přípravku“) uzavírají („datum účinnosti dohody ke specifickému přípravku“) mezisebou EBMT, the European Group for Blood and Marrow transplantation, EBMT, Evropskátransplantace krve a kostní společnosti pro legally represented by A. Gusi dřeně, kterou právně zastupuje A. Gusi hereinafter referred to as “EBMT”. dále jen „EBMT“. AND A Hospital name, address hospital represented by name, CEO, hereinafter referred to as “name hospital” or “Participating Site”. Fakultní nemocnice Plzeň, Edvarda Beneše 1128/13, 305 99 Plzeň, kterou zastupuje MUDr. Václav Šimánek, Ph.D., dále jen„FN Plzeň“ a XXX. Hematologicko-onkologické oddělení, alej Svobody 80, 304 60 Plzeň „zúčastněné pracoviště“. University Hospital Pilzen and EBMT are hereinafter individually
